
Lipum AB
LIPUM | ST
Overview
Corporate Details
- ISIN(s):
- SE0015660899 (+1 more)
- LEI:
- 549300V7JL0004BHBD93
- Country:
- Sweden
- Address:
- Tvistevägen 48 C, 907 36 Umeå
- Website:
- https://lipum.se/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead drug candidate, SOL-116, is a humanized antibody offering a potential first-in-class treatment. It employs a unique mechanism of action by targeting the protein Bile Salt-Stimulated Lipase (BSSL), a novel target in inflammation. Lipum's primary focus is on conditions such as rheumatoid arthritis (RA), with the goal of improving the quality of life for patients. The company has successfully completed a Phase 1 clinical trial for SOL-116, with results supporting its continued development.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Lipum AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
No filings match the current criteria. |
Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Lipum AB via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2025-04-14 | Peter Hovstadius | Other | Sell | 2,000 | 28,260.00 SEK |
2025-04-14 | Peter Hovstadius | Other | Sell | 1,500 | 22,770.00 SEK |
2025-04-14 | Peter Hovstadius | Other | Sell | 1,500 | 21,030.00 SEK |